Basic Information
Ofev
Regulatory Information
EMEA/H/C/003821
January 14, 2015
November 20, 2014
28
August 22, 2024
Company Information
Germany
Binger Strasse 173 55216 Ingelheim am Rhein
Boehringer Ingelheim International GmbH
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Overview Summary
Ofev is a medicine used to treat adults with: - idiopathic pulmonary fibrosis (IPF), a disease of unknown cause in which fibrous tissue forms in the lungs; - systemic sclerosis associated interstitial lung disease, a disease in which the immune system (the body’s natural defences) is overactive, causing production of fibrous tissue and progressive scarring of the lungs; - other chronic fibrosing interstitial lung diseases which are progressive. Ofev contains the active substance nintedanib.